2. Academic Validation
  3. Ceftolozane/tazobactam: place in therapy

Ceftolozane/tazobactam: place in therapy

  • Expert Rev Anti Infect Ther. 2018 Apr;16(4):307-320. doi: 10.1080/14787210.2018.1447381.
Daniele Roberto Giacobbe 1,  Matteo Bassetti 2,  Francesco Giuseppe De Rosa 3,  Valerio Del Bono 1,  Paolo Antonio Grossi 4,  Francesco Menichetti 5,  Federico Pea 6,  Gian Maria Rossolini 7 8,  Mario Tumbarello 9,  Pierluigi Viale 10,  Claudio Viscoli 1,  ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva)
Affiliations

Affiliations

  • 1 a Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia and Department of Health Sciences , University of Genoa , Genoa , Italy.
  • 2 b Infectious Diseases Clinic, Department of Medicine , University of Udine and Azienda Sanitaria Universitaria Integrata Presidio Ospedaliero Universitario Santa Maria della Misericordia , Udine , Italy.
  • 3 c Department of Medical Sciences , University of Turin, Infectious Diseases, City of Health and Sciences , Turin , Italy.
  • 4 d Department of Surgical and Morphological Sciences of Clinical Medicine , University of Insubria , Varese , Italy.
  • 5 e Infectious Diseases Clinic , Nuovo Santa Chiara University Hospital, Azienda Ospedaliera Universitaria Pisana , Pisa , Italy.
  • 6 f Institute of Clinical Pharmacology , Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata Presidio Ospedaliero Universitario Santa Maria della Misericordia , Udine , Italy.
  • 7 g Department of Experimental and Clinical Medicine , University of Florence , Florence , Italy.
  • 8 h Clinical Microbiology and Virology Unit , Florence Careggi University Hospital , Florence , Italy.
  • 9 i Institute of Infectious Diseases , Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli , Rome , Italy.
  • 10 j Department of Medical and Surgical Sciences , University of Bologna , Bologna , Italy.
PMID: 29493397 DOI: 10.1080/14787210.2018.1447381
Abstract

Ceftolozane/tazobactam (C/T) is a new Antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A trial on hospital-acquired pneumonia is ongoing. Areas covered: The place in therapy of C/T is delineated by addressing the following main topics: (i) antimicrobial properties; (ii) pharmacological properties; (iii) results of clinical studies. Expert commentary: C/T is approved for cIAI and cUTI. However, the drug has a special value for clinicians in any kind of infectious localization for two main reasons. The first is that C/T is especially valuable in suspected or documented severe infections due to MDR P. aeruginosa, which is not a rare occurrence in many countries. The second is that C/T may provide an alternative to carbapenems for the treatment of infections caused by ESBL-producers, thus allowing a carbapenem-sparing strategy. Reporting of off-label use is mandatory to increase the body of evidence and the clinicians' confidence in using it for indications other than cIAI and cUTI.

Keywords

Antimicrobial resistance; ESBL; Enterobacteriaceae; MDR; Pseudomonas; carbapenem-sparing; ceftolozane; tazobactam.

Figures
Products